Bristol Myers Squibb expanded its partnership with Nvidia to build a large AI “factory” for life sciences, including planned deployment of NVIDIA DGX SuperPOD infrastructure. BMS said the effort is designed to create one of the most powerful AI systems in pharma. The company reported that AI tools have already reduced the drug-discovery timeline by 20% to 30% in its internal workflows. BMS said the infrastructure is intended to support a hybrid intelligence approach—combining AI co-scientists with human judgment for program selection. Nvidia’s model is gaining traction across pharma: BMS joins other large players that have signed similar deals, signaling continued emphasis on compute-heavy discovery capabilities as data and development cycles accelerate.